Blockchain Registration Transaction Record

TransCode & Quantum Leap Launch Trial for RNA Cancer Drug Targeting Recurrence

TransCode Therapeutics partners with Quantum Leap to test TTX-MC138 in a Phase 2a trial for colorectal cancer patients at high risk of recurrence, targeting minimal residual disease.

This collaboration addresses a critical unmet need in cancer care: preventing recurrence in patients with minimal residual disease. For colorectal cancer patients who have undergone initial treatment but remain at high risk of relapse due to ctDNA positivity, current options are limited. A successful therapy like TTX-MC138 could transform post-treatment monitoring from passive waiting into an active intervention phase, potentially improving survival rates and quality of life. It represents a shift toward precision medicine in oncology, targeting specific biomarkers of metastasis before tumors regrow. For the biotech and investment communities, it highlights the growing pipeline of RNA-based therapeutics and strategic partnerships accelerating clinical development in high-need oncology areas.